(Q44051692)

29 November 2017

title

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus (English)

1 reference

29 November 2017

1 reference

1 reference

Reynolds LR

1

1 reference

29 November 2017

Konz EC

series ordinal

2

1 reference

29 November 2017

Frederich RC

series ordinal

3

1 reference

29 November 2017

Anderson JW

series ordinal

4

1 reference

29 November 2017

publication date

1 July 2002

1 reference

Diabetes, Obesity and Metabolism

29 November 2017

published in

1 reference

29 November 2017

volume

4

1 reference

29 November 2017

issue

4

1 reference

29 November 2017

page(s)

270-275

1 reference

Pharmacologic therapy for type 2 diabetes mellitus

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Racial and ethnic differences in glycemic control of adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Medical hazards of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Obesity, weight loss and prognosis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Diabetic diets and nutritional recommendations: what happens in real life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Clinical evaluation of a minimal intervention meal replacement regimen for weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Weight control in the physician's office

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

The prevention and treatment of obesity. Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Overweight, obesity, and blood pressure: the effects of modest weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Intentional weight loss and mortality among overweight individuals with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

Long-term weight maintenance after an intensive weight-loss program

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00207.X

10.1046/J.1463-1326.2002.00207.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference